Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis upbeat as drugmakers see hospitals coping with COVID

10/27/2020 | 10:21am EDT
FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison

ZURICH (Reuters) - Novartis joined rivals Merck, Johnson & Johnson and Roche in predicting the worst of the pandemic may be over for drugmakers, amid signs healthcare systems have learned how to cope with surging infections without shutting down all services.

The Swiss company nudged up its 2020 profit guidance on Tuesday, now expecting operating income growth in a low-to-mid double-digit percentage range, compared with a low double-digit rate forecast previously.

Merck also raised its profit outlook on Tuesday, following Johnson & Johnson, while Roche last week stuck to sales forecasts and predicted a rebound from pandemic disruptions would continue.

While Novartis CEO Vas Narasimhan acknowledged COVID-19 could still derail 2020 goals, he said hospitals, doctors and patients had learned from painful lockdowns earlier this year that delayed treatment and hit drug sales.

"There's a strong desire not to repeat that," he said, adding U.S. healthcare systems appeared to be "a bit more resilient" in maintaining services than in Europe as the second COVID-19 wave intensifies.

Novartis's third-quarter core net income climbed 8% to $3.47 billion, above analysts' mean forecast of $3.32 billion.

However, sales rose just 1% to $12.3 billion, missing a $12.7 billion forecast. Novartis shares were down 3.5% at 1420 GMT, the biggest fall on the benchmark Swiss Market Index.

Other firms echoed Novartis's view, even as global COVID-19 cases rise by more than 400,000 a day and some countries see intensive care units at capacity within weeks.

"Our confidence is further reinforced by the ability of the health care systems around the world to adapt and deliver care," Merck Chief Financial Officer Robert Davis told investors, adding a pick up in elective surgeries had lifted demand.

A week ago, Roche CEO Severin Schwan called a second "healthcare lockdown" unlikely.

Still, countries including Germany, France, Spain, Switzerland, and the Czech Republic are either enacting or preparing new restrictions.

So Novartis remains on alert.

"Of course, if there would be a resurgence of COVID-19 impact on the health care systems and prescribing behavior in our major markets, there is a scenario of lower sales growth," finance chief Harry Kirsch told investors.

(Reporting by John Miller; editing by Brenna Hughes Neghaiwi and Mark Potter)

By John Miller

ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CREDIT SUISSE GROUP AG -0.21% 9.386 Delayed Quote.-17.47%
NOVARTIS AG 0.36% 86.03 Delayed Quote.2.47%
ROCHE HOLDING AG -0.03% 348.25 Delayed Quote.12.70%
All news about NOVARTIS AG
06/20NOVARTISá : Gene Therapy Zolgensma Shows Efficacy in Children With Spinal Muscul..
06/18NOVARTISá : Study Shows Improved Motor Function in Children with Spinal Muscular..
06/18PRESS RELEASEá : Novartis: New Zolgensma data -3-
06/18PRESS RELEASEá : Novartis: New Zolgensma data -2-
06/18PRESS RELEASEá : Novartis: New Zolgensma data demonstrate age-appropriate develo..
06/18NOVARTISá : New Zolgensma data demonstrate age-appropriate development when used..
06/18CureVac Could Allow Manufacturing Partners To Produce Rival Vaccines
06/17NOVARTIS INDIAá : Consolidated Net Profit Climbs in Fiscal Q4
06/17CureVac may let contractors make rival vaccines if own shot fails -CEO
06/17CureVac may let contractors make rival vaccines if own shot fails - CEO
More news
Financials (USD)
Sales 2021 51 668 M - -
Net income 2021 9 938 M - -
Net Debt 2021 22 978 M - -
P/E ratio 2021 20,7x
Yield 2021 3,53%
Capitalization 208 B 209 B -
EV / Sales 2021 4,48x
EV / Sales 2022 4,19x
Nbr of Employees 110 000
Free-Float 87,4%
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 106,77 $
Last Close Price 92,83 $
Spread / Highest target 60,4%
Spread / Average Target 15,0%
Spread / Lowest Target -5,68%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.47%208 642
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
ABBVIE INC.5.57%199 795